Barclays reaffirmed their hold rating on shares of Validus (NYSE:VR) in a research note issued to investors on Tuesday. Barclays currently has a $50.00 target price on the insurance provider’s stock.

Other equities analysts have also recently issued research reports about the company. Keefe, Bruyette & Woods upgraded Validus from a market perform rating to an outperform rating in a report on Thursday, January 4th. ValuEngine cut Validus from a buy rating to a hold rating in a report on Wednesday, October 11th. Zacks Investment Research upgraded Validus from a strong sell rating to a hold rating in a report on Thursday, October 5th. Buckingham Research assumed coverage on Validus in a report on Monday, September 11th. They set a buy rating and a $52.00 price target for the company. Finally, UBS Group cut their price target on Validus from $57.00 to $50.00 and set a neutral rating for the company in a report on Tuesday, September 19th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $54.33.

Validus (NYSE:VR) remained flat at $$46.61 during trading hours on Tuesday. The stock had a trading volume of 435,480 shares, compared to its average volume of 586,266. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.95 and a current ratio of 0.95. Validus has a twelve month low of $41.15 and a twelve month high of $58.76.

Validus (NYSE:VR) last released its earnings results on Thursday, October 26th. The insurance provider reported ($3.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.30) by $0.08. Validus had a negative return on equity of 0.49% and a negative net margin of 1.38%. The firm had revenue of $407.00 million during the quarter, compared to analysts’ expectations of $453.04 million. During the same quarter last year, the business posted $1.02 earnings per share. The firm’s revenue was up 24.3% on a year-over-year basis. analysts forecast that Validus will post -0.3 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 15th were issued a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a yield of 3.26%. The ex-dividend date of this dividend was Thursday, December 14th. Validus’s dividend payout ratio is presently -233.84%.

In other news, President Kean Driscoll sold 6,875 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $46.16, for a total value of $317,350.00. Following the completion of the sale, the president now directly owns 110,858 shares of the company’s stock, valued at approximately $5,117,205.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Lixin Zeng sold 26,136 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $52.10, for a total value of $1,361,685.60. Following the completion of the sale, the chief executive officer now directly owns 57,855 shares of the company’s stock, valued at $3,014,245.50. The disclosure for this sale can be found here. Insiders have sold a total of 39,886 shares of company stock valued at $2,024,848 in the last 90 days. 2.33% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Validus in the 2nd quarter valued at approximately $116,000. Zions Bancorporation bought a new stake in shares of Validus in the 3rd quarter valued at approximately $116,000. The Manufacturers Life Insurance Company lifted its stake in shares of Validus by 10.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,382 shares of the insurance provider’s stock valued at $124,000 after purchasing an additional 219 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in shares of Validus by 93.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,650 shares of the insurance provider’s stock valued at $138,000 after purchasing an additional 1,282 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Validus by 10.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,905 shares of the insurance provider’s stock valued at $151,000 after purchasing an additional 278 shares during the last quarter. 96.24% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Validus (VR) Earns “Hold” Rating from Barclays” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/validus-vr-earns-hold-rating-from-barclays/1805817.html.

About Validus

Validus Holdings, Ltd. is a holding company. The Company operates through four segments: Validus Re, Talbot, Western World and AlphaCat. Validus Re is a Bermuda-based reinsurance segment focused treaty reinsurance. Validus Re concentrates on first-party property and other reinsurance risks. Talbot is a specialty insurance segment operating within the Lloyd’s insurance market through Syndicate 1183.

Analyst Recommendations for Validus (NYSE:VR)

Receive News & Ratings for Validus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Validus and related companies with Analyst Ratings Network's FREE daily email newsletter.